First-Line Persistence of Biologics in Psoriasis from a Cohort Based on French Medico-Administrative Data

Many biologics are available for psoriasis; their effectiveness/safety have been compared in real-life studies on the basis of their persistence (time between therapy initiation and discontinuation). Existing studies are limited by the low number of patients included, especially for the most recently marketed molecules (IL-23 inhibitor [IL-23i] agents) ( Egeberg et al., 2018 Egeberg A. Ottosen M.B. Gniadecki R. Broesby-Olsen S. Dam T.N. Bryld L.E. et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018; 178: 509-519 Crossref PubMed Scopus (212) Google Scholar ; Menter et al., 2016 Menter A. Papp K.A. Gooderham M. Pariser D.M. Augustin M. Kerdel F.A. et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016; 30: 1148-1158 Crossref PubMed Scopus (188) Google Scholar ; Schmitt-Egenolf et al., 2021 Schmitt-Egenolf M. Freilich J. Stelmaszuk-Zadykowicz N.M. Apol E. Hansen J.B. Levin L.Å. Drug persistence of biologic treatments in psoriasis: A Swedish national population study. Dermatol Ther (Heidelb). 2021; 11: 2107-2121 Crossref PubMed Scopus (11) Google Scholar ; Yiu et al., 2022 Yiu Z.Z.N. Becher G. Kirby B. Laws P. Reynolds N.J. Smith C.H. et al. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA Dermatol. 2022; 158: 1131-1141 Crossref Scopus (9) Google Scholar ).